S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Laser breakthrough could send stock soaring 2,467% (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Laser breakthrough could send stock soaring 2,467% (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Laser breakthrough could send stock soaring 2,467% (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Laser breakthrough could send stock soaring 2,467% (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Laser breakthrough could send stock soaring 2,467% (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Laser breakthrough could send stock soaring 2,467% (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Laser breakthrough could send stock soaring 2,467% (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Laser breakthrough could send stock soaring 2,467% (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
NASDAQ:OLMA

Olema Pharmaceuticals (OLMA) Stock Forecast, Price & News

$6.31
+0.36 (+6.05%)
(As of 06/6/2023 ET)
Compare
Today's Range
$5.72
▼
$6.42
50-Day Range
$3.22
▼
$7.27
52-Week Range
$2.19
▼
$7.45
Volume
140,921 shs
Average Volume
178,051 shs
Market Capitalization
$257.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.25
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Olema Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
141.7% Upside
$15.25 Price Target
Short Interest
Bearish
2.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.79) to ($2.92) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

512th out of 981 stocks

Pharmaceutical Preparations Industry

239th out of 459 stocks

See Top Rated MarketRank™ Stocks Here

OLMA stock logo

About Olema Pharmaceuticals (NASDAQ:OLMA) Stock

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Receive OLMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Olema Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

OLMA Stock News Headlines

May 30, 2023 | finance.yahoo.com
Olema Oncology to Present at the 2023 Jefferies Healthcare Conference
May 19, 2023 | finance.yahoo.com
Institutional investors own a significant stake of 42% in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
June 7, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
May 16, 2023 | americanbankingnews.com
Q3 2023 Earnings Estimate for Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Issued By Capital One Financial
May 13, 2023 | americanbankingnews.com
Capital One Financial Raises Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $20.00
May 11, 2023 | msn.com
HC Wainwright & Co. Maintains Olema Pharmaceuticals (OLMA) Buy Recommendation
May 11, 2023 | finance.yahoo.com
Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study
May 10, 2023 | americanbankingnews.com
HC Wainwright Lowers Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $14.00
June 7, 2023 | Legacy Research (Affiliate) (Ad)
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
May 9, 2023 | finance.yahoo.com
Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 8, 2023 | finance.yahoo.com
Olema Oncology Announces Upcoming Poster Presentation at the 2023 ESMO Breast Cancer Annual Congress
May 6, 2023 | americanbankingnews.com
Olema Pharmaceuticals (NASDAQ:OLMA) Now Covered by Analysts at Capital One Financial
May 5, 2023 | americanbankingnews.com
Olema Pharmaceuticals (NASDAQ:OLMA) Coverage Initiated at Capital One Financial
May 2, 2023 | americanbankingnews.com
Lifesci Capital Weighs in on Olema Pharmaceuticals, Inc.'s FY2023 Earnings (NASDAQ:OLMA)
April 29, 2023 | americanbankingnews.com
Olema Pharmaceuticals (NASDAQ:OLMA) Receives "Outperform" Rating from Lifesci Capital
April 29, 2023 | americanbankingnews.com
Olema Pharmaceuticals (NASDAQ:OLMA) Rating Reiterated by Lifesci Capital
April 29, 2023 | americanbankingnews.com
Lifesci Capital Reiterates "Outperform" Rating for Olema Pharmaceuticals (NASDAQ:OLMA)
April 13, 2023 | finance.yahoo.com
Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference
March 11, 2023 | marketwatch.com
Olema Pharmaceuticals to Reduce Workforce by 25% Amid Broader Restructuring
March 11, 2023 | seekingalpha.com
Olema Pharmaceuticals GAAP EPS of -$0.65 in-line
March 10, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: aTyr Pharma (LIFE), COMPASS Pathways (CMPS) and Olema Pharmaceuticals (OLMA)
March 9, 2023 | seekingalpha.com
OLMA
March 9, 2023 | finance.yahoo.com
Olema Oncology Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Strategic Update
March 2, 2023 | benzinga.com
Olema Oncology to Present at Oppenheimer 33rd Annual Healthcare Conference
February 21, 2023 | finance.yahoo.com
Olema Oncology to Participate at Upcoming Investor Conferences
January 2, 2023 | finance.yahoo.com
We Think Olema Pharmaceuticals (NASDAQ:OLMA) Needs To Drive Business Growth Carefully
December 7, 2022 | finance.yahoo.com
Olema Oncology Announces OP-1250 Demonstrates Attractive Combinability with CDK 4/6 Inhibitor Palbociclib in Phase 1b Dose Escalation Study
See More Headlines

OLMA Price History

OLMA Company Calendar

Last Earnings
3/09/2023
Today
6/06/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OLMA
CUSIP
N/A
CIK
1750284
Web
www.olema.com
Phone
650-243-5555
Fax
N/A
Employees
73
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.25
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+142.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.74)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-104,790,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-53.26%
Return on Assets
-49.24%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.76
Quick Ratio
9.76

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.90 per share
Price / Book
1.28

Miscellaneous

Outstanding Shares
40,760,000
Free Float
31,183,000
Market Cap
$256.38 million
Optionable
Not Optionable
Beta
2.32

Key Executives

  • Dr. Sean P. Bohen M.D. (Age 56)
    Ph.D., Pres, CEO & Director
    Comp: $999.3k
  • Mr. Shane William Charles Kovacs M.B.A. (Age 49)
    Chief Operating & Financial Officer
    Comp: $875.55k
  • Dr. Cyrus L. Harmon Ph.D. (Age 52)
    Chief Research Officer & Director
  • Mr. Kinney HornMr. Kinney Horn (Age 49)
    Chief Bus. Officer
    Comp: $588.3k
  • Dr. Peter J. Kushner Ph.D. (Age 84)
    Co-Founder & Sr. Research Fellow
  • Ms. Courtney Dugan
    VP of Investor Relations & Communications
  • Mr. John B. Moriarty Jr. (Age 55)
    Exec. VP, Chief Legal Officer & Corp. Sec.
  • Ms. Julie Dexter
    VP & Head of People
  • Dr. David C. Myles Ph.D. (Age 60)
    Chief Discovery & Non-Clinical Devel. Officer
  • Ms. Demiana Faltaos Ph.D.
    Pharm.D., VP & Head of Clinical Pharmacology

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













OLMA Stock - Frequently Asked Questions

Should I buy or sell Olema Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Olema Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OLMA shares.
View OLMA analyst ratings or view top-rated stocks.

What is Olema Pharmaceuticals' stock price forecast for 2023?

5 brokers have issued 1-year price targets for Olema Pharmaceuticals' stock. Their OLMA share price forecasts range from $11.00 to $20.00. On average, they expect the company's stock price to reach $15.25 in the next twelve months. This suggests a possible upside of 142.4% from the stock's current price.
View analysts price targets for OLMA or view top-rated stocks among Wall Street analysts.

How have OLMA shares performed in 2023?

Olema Pharmaceuticals' stock was trading at $2.45 at the beginning of the year. Since then, OLMA stock has increased by 156.7% and is now trading at $6.29.
View the best growth stocks for 2023 here.

When is Olema Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our OLMA earnings forecast.

How were Olema Pharmaceuticals' earnings last quarter?

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) released its earnings results on Thursday, March, 9th. The company reported ($0.65) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.65).

When did Olema Pharmaceuticals IPO?

(OLMA) raised $170 million in an initial public offering on Thursday, November 19th 2020. The company issued 10,000,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Cowen and Canaccord Genuity served as the underwriters for the IPO.

What is Olema Pharmaceuticals' stock symbol?

Olema Pharmaceuticals trades on the NASDAQ under the ticker symbol "OLMA."

Who are Olema Pharmaceuticals' major shareholders?

Olema Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.45%), Sectoral Asset Management Inc. (2.45%), Geode Capital Management LLC (0.86%), Vontobel Holding Ltd. (0.83%), Renaissance Technologies LLC (0.63%) and Deutsche Bank AG (0.63%). Insiders that own company stock include Bvf Partners L P/Il, Cormorant Asset Management, Lp, Cyrus Harmon, G Walmsley Graham, Kinney Horn and Sean Bohen.
View institutional ownership trends.

How do I buy shares of Olema Pharmaceuticals?

Shares of OLMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Olema Pharmaceuticals' stock price today?

One share of OLMA stock can currently be purchased for approximately $6.29.

How much money does Olema Pharmaceuticals make?

Olema Pharmaceuticals (NASDAQ:OLMA) has a market capitalization of $256.38 million. The company earns $-104,790,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis.

How can I contact Olema Pharmaceuticals?

Olema Pharmaceuticals' mailing address is 512 2ND STREET 4TH FLOOR, SAN FRANCISCO CA, 94107. The official website for the company is www.olema.com. The company can be reached via phone at 650-243-5555 or via email at ir@olema.com.

This page (NASDAQ:OLMA) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -